HOPA Annual Conference - Hematology/Oncology Pharmacy Association Annual Conference

Site-of-care considerations can pose challenges with these therapies.

Danielle Roman, PharmD, BCOP, discusses the efficacy and safety outcomes of CDK4/6 inhibitors in early-stage breast cancer, as well as key considerations for CDK4/6 inhibitors in this indication.

Kirollos Hanna, PharmD, BCPS, BCOP, FACCC, addresses some common challenges pharmacists may be facing when looking to operationalize bispecifics at their facilities.

Kirollos Hanna, PharmD, BCPS, BCOP, FACCC, discusses the role of the pharmacist in relation to bispecific care team readiness and patient readiness.

Scott Soefje, PharmD, BCOP, FCCP, FHOPA, MBA, addresses some of the key steps pharmacists should take when conducting a financial analysis for cancer drugs.

Whitney Lewis, PharmD, BCOP, discusses how the treatment armamentarium for NSCLC has expanded in recent years and the associated cause for this acceleration.

Kirollos Hanna, PharmD, BCPS, BCOP, FACCC, addresses some of the considerations for bispecifics in relation to facility readiness at different sites and among different stakeholders.

Danielle Roman, PharmD, BCOP, discusses how the role of the oncology pharmacist has changed in recent years in optimizing early-stage breast cancer treatment with targeted therapies.

Karen Fancher, PharmD, BCOP, discusses some guiding principles for oncology pharmacists when facing ethical dilemmas and provides some recommendations for navigating those challenges.

Although the number of clinical trials has quadrupled, the number of FDA approvals remains stable over a 10-year period, highlighting workforce challenges in clinical research.

There are unique complexities when implementing bispecific antibodies, including site of care considerations, monitoring, and management of adverse events.

These FDA-approved therapies are used to treat lymphoma after 2 or more lines of therapy and represent significant advancements in the treatment of lymphoma.

FDA-approved BiTE therapies for relapsed/refractory multiple myeloma show promising response rates, offering off-the-shelf alternatives to CAR T therapy.

Precision medicine revolutionized NSCLC treatment, targeting specific mutations like KRAS G12C with therapies such as adagrasib to improve patient outcomes.

It would also be beneficial to include a patient’s entire healthcare team in this management strategy, said an expert at the Hematology/Oncology Pharmacy Association (HOPA) Annual Conference 2023 in Phoenix, Arizona.

Consistent toxicity management and education reinforcement can improve the patient’s treatment management strategy.

Improving the process of safe medication therapy management requires comfort, trust, and fostering a culture for safe communication.

Oncology pharmacist discusses recent clinical trial data and what it could mean for patient outcomes.

Factors (comorbidities, social factors) can largely affect the success of therapies in daily practice, despite findings observed in clinical trials.

And whatever specialty the student or resident decides on, it does not have to define the rest of their career.

Creating a safe environment for LGBTQ+ patients through the use of trauma informed care is critical to ensuring they feel comfortable returning to the clinic in the future.

There has been a historical lack of complete or appropriate data on sexual and gender minority groups, leading to difficulties in analyzing health outcomes in LGBTQ+ community.

Despite the potential for clinical benefit, triplet therapies have added complexities, monitoring needs, toxicities, and costs associated with additional pharmacologic therapy.

If patients with G6PD deficiency are exposed to risk factors, such as certain medications, environmental factors, or foods, it can lead to hemolysis.

Pharmacists have an important role in helping patients to identify treatment-related toxicities and manage symptoms to help the transition to the outpatient setting.

Some specialty pharmacy programs are even using electronic medical records to send survey tools to patients.

Expert notes significant advances in the treatment of multiple myeloma, large B cell lymphomas, and acute myeloid leukemia, during a presentation at HOPA 2023 Annual Conference.

The Hematology/Oncology Pharmacy Association (HOPA) created committees, inclusion statements, and diversity, equity, and inclusion (DEI) checkpoints to improve healthcare for underserved or historically less included populations.

Before tapering patients treated for cancer off of opioids, care providers should first establish what the goals of tapering are.

Certain populations have been found to have differing prognoses, such as African American patients, who have an earlier onset of disease with a higher likelihood of an aggressive tumor type and shorter survival.